PROLYNX
ProLynx develops advanced linker technologies and a facile with a transformative platform for controlled release of therapeutics from circulating and fixed macromolecular conjugates. The company's technology is dedicated to the development of linker systems to enable predictable and controllable half-extension of drugs. ProLynx was founded in 2009 by Daniel V. Santi and Gary W. Ashley and is based in San Francisco, California.
PROLYNX
Social Links:
Industry:
Biotechnology Health Care Therapeutics
Founded:
2009-01-01
Address:
San Francisco, California, United States
Country:
United States
Website Url:
http://www.prolynxinc.com
Total Employee:
1+
Status:
Active
Contact:
+1 415-552-5306
Total Funding:
2.32 M USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta SPF Google Font API Google Maps Content Delivery Network SSL By Default JsDelivr Apache AJAX Libraries API
Similar Organizations
D2M Biotherapeutics
D2M Biotherapeutics focuses on the development of novel immunotherapeutics.
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Current Employees Featured
Founder
Investors List
National Institutes of Health
National Institutes of Health investment in Grant - ProLynx
National Institutes of Health
National Institutes of Health investment in Grant - ProLynx
National Science Foundation
National Science Foundation investment in Grant - ProLynx
National Science Foundation
National Science Foundation investment in Grant - ProLynx
National Science Foundation
National Science Foundation investment in Grant - ProLynx
National Science Foundation
National Science Foundation investment in Grant - ProLynx
National Science Foundation
National Science Foundation investment in Grant - ProLynx
National Institutes of Health
National Institutes of Health investment in Grant - ProLynx
National Institutes of Health
National Institutes of Health investment in Grant - ProLynx
National Institutes of Health
National Institutes of Health investment in Grant - ProLynx
Official Site Inspections
http://www.prolynxinc.com Semrush global rank: 5.34 M Semrush visits lastest month: 1.42 K
- Host name: 199.114.180.107.host.secureserver.net
- IP address: 107.180.114.199
- Location: Scottsdale United States
- Latitude: 33.6013
- Longitude: -111.8867
- Metro Code: 753
- Timezone: America/Phoenix
- Postal: 85260
More informations about "ProLynx"
ProLynx - Crunchbase Company Profile & Funding
Contact Email [email protected] Phone Number +1 415-552-5306 ProLynx develops advanced linker technologies and a facile with a transformative platform for controlled release of therapeutics from circulating and fixed …See details»
ProLynx - Overview, News & Similar companies | ZoomInfo.com
ProLynx contact info: Phone number: (415) 552-5306 Website: www.prolynxinc.com What does ProLynx do? About ProLynx: ProLynx LLC is a privately held biotechnology company located …See details»
ProLynx - LinkedIn
ProLynx | 593 followers on LinkedIn. ProLynx Inc is a clinical-stage biopharmaceutical company specializing in the development of novel long-acting therapeutics. We are leveraging our drug ...See details»
ProLynx Company Profile 2024: Valuation, Funding
Information on valuation, funding, cap tables, investors, and executives for ProLynx. Use the PitchBook Platform to explore the full profile.See details»
ProLynx Company Profile - Office Locations, Competitors ... - Craft
ProLynx is a company developing a platform for controlled release of therapeutics from circulating and fixed macromolecular conjugates. It offers linker systems to enable predictable and …See details»
ProLynx appoints Richard King as Chief Executive Officer and Chris ...
SAN FRANCISCO, Sept. 20, 2022 (GLOBE NEWSWIRE) -- ProLynx, Inc., a biotechnology company with a novel platform technology for half-life extension of therapeutics, enabling …See details»
ProLynx announces initiation of the Phase II Topology
Mar 25, 2024 ProLynx is a San Francisco biotechnology company developing proprietary systems to improve the pharmacokinetics and efficacy of important therapies …See details»
ProLynx appoints Richard King as Chief Executive Officer
SAN FRANCISCO, Sept. 20, 2022 (GLOBE NEWSWIRE) -- ProLynx, Inc., a biotechnology company with a novel platform technology for half-life extension of...See details»
ProLynx Inc
ProLynx ß-Eliminative Drug Delivery System. One major challenge in drug development is achieving the optimal residence time for a drug – often measured by its “half-life” in the body.See details»
ProLynx announces initiation of Phase I/II clinical trial of its DNA ...
SAN FRANCISCO, Feb. 05, 2024 (GLOBE NEWSWIRE) -- ProLynx Inc. announced today that the first patient was treated with PLX038 (PEGylated SN-38) in a Phase I/II clinical trial for …See details»
ProLynx announces preclinical results of long-acting semaglutide ...
SAN FRANCISCO, Aug. 21, 2024 (GLOBE NEWSWIRE) -- ProLynx Inc. today announced the use of their technology to create a long-acting semaglutide that can be administered once …See details»
ProLynx Inc
News. Aug 2024 ProLynx announces preclinical results of long-acting semaglutide requiring once monthly dosing. Mar 2024 ProLynx announces initiation of the Phase II Topology clinical trial …See details»
ProLynx appoints Richard King as Chief Executive Officer and Chris ...
[email protected]. Title: Prolynx_PR2022 Author: leah santi Created Date: 9/21/2022 3:01:26 AM ...See details»
ProLynx announces initiation of Phase II clinical trial of its DNA ...
SAN FRANCISCO, Oct. 07, 2022 (GLOBE NEWSWIRE) -- ProLynx Inc. today announced that the first patient was treated with PLX038 (PEG~SN-38) in a Phase II clinical trial for platinum …See details»
Publications - ProLynx Inc
Publications. You may have noticed that Prolynx scientists value publishing their novel research in high-quality, peer-reviewed-journals. We are proud to be the sole ...See details»
ProLynx announces initiation of Phase II clinical trial of its DNA ...
SAN FRANCISCO, Oct. 07, 2022 (GLOBE NEWSWIRE) -- ProLynx Inc. today announced that the first patient was treated with PLX038 (PEG~SN-38) in a Phase II clinical trial for platinum …See details»
ProLynx announces a publication proposing that a long-acting …
SAN FRANCISCO, Jan. 24, 2024 (GLOBE NEWSWIRE) -- ProLynx Inc., a biotech company with a unique technology for tunable half-life extension of drugs, announced publication of a paper …See details»
ProLynx announces initiation of Phase II clinical trial of
SAN FRANCISCO, Oct. 07, 2022 (GLOBE NEWSWIRE) -- ProLynx Inc. today announced that the first patient was treated with PLX038 (PEG~SN-38) in a Phase II clinical trial for platinum …See details»
ProLynx Inc
Pipeline. PLX038: Our lead product in Phase II oncology clinical trials. PLX376 long-acting PARP inhibitor: ProLynx is developing a long-acting PEG-PARP inhibitor in which a single injection …See details»